#USA #Cincinnati #Anaphylaxis #FARE #Anatool

Anatool: Transforming Anaphylaxis Recognition and Treatment

In a significant development for healthcare providers, Cincinnati Children's Hospital Medical Center has introduced Anatool, a new clinical support tool aimed at enhancing the recognition and treatment of anaphylaxis, a severe allergic reaction that can be life-threatening. This tool, which draws from international consensus recommendations, offers real-time guidance to healthcare professionals across various clinical settings.

Currently, many patients experiencing anaphylaxis do not receive timely treatment with epinephrine, even when they meet the criteria for its administration. Dr. Tim Dribin, who co-developed Anatool, highlights that this issue often arises from inconsistent definitions and treatment protocols among clinicians and healthcare systems. By providing a unified framework based on a landmark report published in The Journal of Allergy and Clinical Immunology, Anatool aims to eliminate discrepancies and ensure that patients receive prompt, evidence-based care at their most critical moments.

Key Features of Anatool

The development of Anatool involved collaboration with FARE (Food Allergy Research & Education) and experts, including Dr. Hugh Sampson from the Icahn School of Medicine and Dr. Antonella Muraro from the University of Padua. The tool is designed for emergency physicians, paramedics, nurses, allergists, urgent care clinicians, and other medical professionals who might encounter anaphylactic patients. Notably, Anatool incorporates the latest diagnostic criteria, offering straightforward guidance on administering epinephrine both intramuscularly and through the novel intranasal delivery method, neffy®, the first FDA-approved needle-free epinephrine treatment available for anaphylaxis.

Anatool’s innovative approach is particularly beneficial in pediatric care, addressing a significant gap in pediatric-specific resources for anaphylaxis management. As Dr. Dribin points out, recognizing anaphylaxis in infants and young children can be particularly challenging, as symptoms may not align with those seen in older children and adults. By integrating specific criteria for infants, Anatool equips providers—many of whom may not regularly treat pediatric patients—with the confidence to make informed decisions when time is of the essence.

A Response to Call for Improved Anaphylaxis Care

The release of this tool comes at a crucial time, emphasizing the continuous need for improvements in anaphylaxis management. Research led by Dr. Dribin and others has shown that there's a frequent underutilization of epinephrine before patients reach hospitals. Their findings indicate that many children who receive epinephrine can be safely discharged sooner than current practice guidelines suggest, thereby reducing unnecessary observation times while maintaining patient safety.

During the recent 2026 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI), FARE underscored the importance of resources like Anatool that empower healthcare professionals to respond efficiently to life-threatening allergic reactions. Sung Poblete, CEO of FARE, remarked, "Food allergy affects 1 in 10 adults in the U.S., and having the right information accessible to healthcare professionals at critical moments can be life-saving. Anatool is a vital tool that enhances our ability to recognize and treat anaphylaxis quickly, ensuring patients have the safety net they require."

Healthcare professionals interested in accessing Anatool can do so via their website at Anatool Website. By making evidence-based care more accessible, Anatool promises to significantly change the approach to anaphylaxis treatment in clinical settings, ultimately safeguarding the lives of individuals facing severe allergic reactions.